(Sharma Ankush) - University of California Department of Internal Medicine
(Houshyar Roozbeh) - University of California Department of Radiological Sciences
(Bhosale Priya) - University of Texas MD Anderson Cancer Center Department of Radiology
ÃÖÁØÀÏ(Choi Joon-Il) - Catholic University College of Medicine Seoul St. Mary¡¯s Hospital Department of Radiology
(Gulati Rajesh) - University of California Department of Internal Medicine
(Lall Chandana) - University of California Department of Radiological Sciences
Abstract
Treating patients undergoing chemotherapy who display findings of liver toxicity, requires a solid understanding of these medications. It is important for any clinician to have an index of suspicion for liver toxicity and be able to recognize it, even on imaging. Cancer chemotherapy has evolved, and newer medications that target cell biology have a different pattern of liver toxicity and may differ from the more traditional cytotoxic agents. There are several hepatic conditions that can result and keen clinical as well as radiographic recognition are paramount. Conditions such as sinusoidal obstructive syndrome, steatosis, and pseudocirrhosis are more commonly associated with chemotherapy. These conditions can display clinical signs of acute hepatitis, liver cirrhosis, and even liver failure. It is important to anticipate and recognize these adverse reactions and thus appropriate clinical action can be taken. Often times, patients with these liver manifestations can be managed with supportive therapies, and liver toxicity may resolve after discontinuation of chemotherapy.
Å°¿öµå
Chemotherapy, Hepatic toxicity, Pseudocirrhosis, Steatosis, Hepatic Necrosis, Hepatitis
KMID :
1103920140200030317
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)